Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

48540

registered interest
date	25/04/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what criteria his Department uses to decide whether to prescribe Kadcyla using funds from the Cancer Drugs Fund.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	196787
answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>NHS England is responsible for administering the Cancer Drugs Fund. Its national Cancer Drugs Fund clinical panel added Kadcyla (trastuzumab emtansine) for the treatment of HER2-positive locally advanced/unresectable or metastatic breast cancer to its national cohort policies list in February 2014. Further information on how the panel made its decision is available at:</p><p> </p><p>www.england.nhs.uk/ourwork/pe/cdf/</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
tabling member	545 label Biography information for Paul Flynn

48577

registered interest
date	25/04/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure the prescription of drugs by doctors is not influenced by financial payments from pharmaceutical companies.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	196748
answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>The offer of gifts and benefits to healthcare professionals is strictly regulated under regulation 300 of the Human Medicines Regulations 2012. This provides that, where medicines are being promoted to healthcare professionals who prescribe or supply medicines, no gift, pecuniary advantage or benefit may be offered or supplied unless it is inexpensive and relevant to the practice of medicine or pharmacy. The Medicines and Healthcare products Regulatory Agency or the industry self-regulatory body, the Prescription Medicines Code of Practice Authority, would investigate any complaint about inappropriate payments made by pharmaceutical companies under this regulation.</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
tabling member	545 label Biography information for Paul Flynn